CELGENE CORPORATION

CD47 inhibitor drugs, targeting cancer cell evasion, are in advanced clinical trials, with magrolimab and evorpacept leading. Combination therapies are key, aiming to enhance efficacy and overcome resistance. Market growth is driven by rising cancer incidence and immunotherapy use, attracting significant investments and partnerships. Challenges include managing toxicity and demonstrating therapeutic advantages. The field is rapidly expanding, with global competition intensifying.